Antares Pharma (NASDAQ:ATRS) is an under the radar biotech company which is starting to make the significant transformation of a royalty based revenue generating company to a fully fledged proprietary product revenue generating bonafide biotech. Its first proprietary product Otrexup has an FDA PDUFA date of October 14, 2013. I am confident that the FDA will approve Otrexup. The biggest bear case against Antares is seeing if management can execute its plan and generate Otrexup revenue, which can organically fund the promising pipeline. This article will feature my investing thesis on why Otrexup will gain FDA approval, why Otrexup commercialization will be incredibly successful and how Antares management will be able to leverage Otrexup gains to...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|
|PRO Top long ideas returned 21.7% in 2016**|